Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes angiogenesis and ischemia-induced neovascularization via NADPH oxidase 4 (NOX4) and nitric oxide-dependent mechanisms

Journal of the American Heart Association

Volumn 4, Issue 11, 2015, Pages

  Di Bartolo, Belinda Ann ^a,c   Cartland, Siân Peta ^a,b,c   Prado Lourenco, Leonel ^b   Griffith, Thomas Scott ^d   Gentile, Carmine ^a,c   Ravindran, Jayant ^b   Azahri, Nor Saadah Muhammad ^b   Thai, Thuan ^b   Yeung, Amanda Wing Shee ^b   Thomas, Shane Ross ^b   Kavurma, Mary Meltem ^a,c  

^a HEART RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Angiogenesis; Endothelial cell; Gene expression; Ischemia

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR 2; HYDROGEN PEROXIDE; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; BIOLOGICAL MARKER; CD31 ANTIGEN; NOS3 PROTEIN, HUMAN; NOX4 PROTEIN, HUMAN; NOX4 PROTEIN, MOUSE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TNFSF10 PROTEIN, HUMAN; TNFSF10 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CAPILLARY ENDOTHELIAL CELL; CELL MIGRATION; CELL PROLIFERATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG MECHANISM; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LASER DOPPLER FLOWMETRY; LIMB ISCHEMIA; LIMB PERFUSION; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA EXTRACTION; VASCULAR SMOOTH MUSCLE CELL; VASCULARIZATION; VIRAL GENE THERAPY; WESTERN BLOTTING; WILD TYPE; ANIMAL; C57BL MOUSE; CAPILLARY; CELL CULTURE; CELL MOTION; DEFICIENCY; DIAGNOSTIC IMAGING; DISEASE MODEL; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; GENOTYPE; HINDLIMB; INTERVENTIONAL ULTRASONOGRAPHY; ISCHEMIA; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TIME FACTOR;

ANIMALS; ANTIGENS, CD31; APOPTOSIS; BIOMARKERS; CAPILLARIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GENOTYPE; HINDLIMB; HUMANS; ISCHEMIA; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; NADPH OXIDASE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84991523359     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002527     Document Type: Article

References (43)

1. Emanueli C, Madeddu P. Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions. B J Pharmacol. 2001;133:951-958.
2. Azahri NS, Kavurma MM. Transcriptional regulation of tumour necrosis factorrelated apoptosis-inducing ligand. Cell Mol Life Sci. 2013;70:3617-3629.
3. Harith HH, Morris MJ, Kavurma MM. On the TRAIL of obesity and diabetes. Trends Endocrinol Metab. 2013;24:578-587.
4. Kavurma MM, Bennett MR. Expression, regulation and function of trail in atherosclerosis. Biochem Pharmacol. 2008;75:1441-1450.
5. Kavurma MM, Tan NY, Bennett MR. Death receptors and their ligands in atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:1694-1702.
6. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-12690.
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;2:673-682.
8. Bisgin A, Yalcin AD, Gorczynski RM. Circulating soluble tumor necrosis factor related apoptosis inducing-ligand (TRAIL) is decreased in type-2 newly diagnosed, non-drug using diabetic patients. Diabetes Res Clin Pract. 2012;96:e84-e86.
9. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, Keren G, George J. The involvement of tumor necrosis factor-related apoptosisinducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol. 2005;45:1018-1024.
10. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis. 2006;184:446-447.
11. Volpato S, Ferrucci L, Secchiero P, Corallini F, Zuliani G, Fellin R, Guralnik JM, Bandinelli S, Zauli G. Association of tumor necrosis factor-related apoptosisinducing ligand with total and cardiovascular mortality in older adults. Atherosclerosis. 2011;215:452-458.
12. Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE, Kavurma MM. TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe (/) mice. Diabetologia. 2011;54:3157-3167.
13. Secchiero P, Candido R, Corallini F, Zacchigna S, Toffoli B, Rimondi E, Fabris B, Giacca M, Zauli G. Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice. Circulation. 2006;114:1522-1530.
14. Di Bartolo BA, Cartland SP, Harith HH, Bobryshev YV, Schoppet M, Kavurma MM. TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One. 2013;8:e74211.
15. Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, Crossman DC, Newman CM, Kiely DG, Francis SE, Lawrie A. Inhibition of tumor necrosis factor-related apoptosisinducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med. 2012;209:1919-1935.
16. Azahri NS, Di Bartolo BA, Khachigian LM, Kavurma MM. Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms for PDGF-BBmediated VSMC proliferation and migration. J Cell Biol. 2012;13:2597-2606.
17. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res. 2010;106:1061-1071.
18. Kavurma MM, Schoppet M, Bobryshev YV, Khachigian LM, Bennett MR. Trail stimulates proliferation of vascular smooth muscle cells via activation of NFkappa B and induction of insulin-like growth factor-1 receptor. J Biol Chem. 2008;283:7754-7762.
19. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R. TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer. 2006;94:1428-1435.
20. Chen PL, Easton AS. Evidence that tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits angiogenesis by inducing vascular endothelial cell apoptosis. Biochem Biophys Res Commun. 2010;391:936-941.
21. Cantarella G, Di Benedetto G, Ribatti D, Saccani-Jotti G, Bernardini R. Involvement of caspase 8 and c-FLIPL in the proangiogenic effects of the tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). FEBS J. 2014;281:1505-1513.
22. Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, Melato M, Zauli G. Evidence for a proangiogenic activity of TNF-related apoptosisinducing ligand. Neoplasia. 2004;6:364-373.
23. Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol. 1998;152:1667-1679.
24. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviralmediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol. 2000;165:2886-2894.
25. Kavurma MM, Khachigian LM. ERK, JNK and p38 MAP kinase regulate proliferation and migration of phenotypically-distinct SMC subtypes. J Cell Biochem. 2003;89:289-300.
26. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis. 2001;4:113-121.
27. Gentile C, Muise-Helmericks RC, Drake CJ. VEGF-mediated phosphorylation of eNOS regulates angioblast and embryonic endothelial cell proliferation. Dev Biol. 2013;373:163-175.
28. Kemp TJ, Kim JS, Crist SA, Griffith TS. Induction of necrotic tumor cell death by TRAIL/Apo-2L. Apoptosis. 2003;8:587-599.
29. Jiang F, Zhang Y, Dusting GJ. NADPH oxidase-mediated redox signaling: roles in cellular stress response, stress tolerance, and tissue repair. Pharmacol Rev. 2011;63:218-242.
30. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2008;10:1713-1765.
31. Schroder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012;110:1217-1225.
32. Craige SM, Chen K, Pei Y, Li C, Huang X, Chen C, Shibata R, Sato K, Walsh K, Keaney JF Jr. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation. 2011;124:731-740.
33. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res. 2005;68:26-36.
34. Murphy PR, Limoges M, Dodd F, Boudreau RT, Too CK. Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. Endocrinology. 2001;142:81-88.
35. Park KJ, Lee CH, Kim A, Jeong KJ, Kim CH, Kim YS. Death receptors 4 and 5 activate Nox1 NADPH oxidase through riboflavin kinase to induce reactive oxygen species-mediated apoptotic cell death. J Biol Chem. 2012;287:3313-3325.
36. Li X, Han WQ, Boini KM, Xia M, Zhang Y, Li PL. TRAIL death receptor 4 signaling via lysosome fusion and membrane raft clustering in coronary arterial endothelial cells: evidence from ASM knockout mice. J Mol Med. 2013;91:25-36.
37. Urao N, Sudhahar V, Kim SJ, Chen GF, McKinney RD, Kojda G, Fukai T, Ushio-Fukai M. Critical role of endothelial hydrogen peroxide in post-ischemic neovascularization. PLoS One. 2013;8:e57618.
38. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011-1027.
39. Giavazzi R, Sennino B, Coltrini D, Garofalo A, Dossi R, Ronca R, Tosatti MP, Presta M. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol. 2003;162: 1913-1926.
40. Lee SC, Cheong HJ, Kim SJ, Yoon J, Kim HJ, Kim KH, Kim SH, Kim HJ, Bae SB, Kim CK, Lee N, Lee KT, Park SK, Hong DS, Park HS, Won JH. Low-dose combinations of LBH589 and TRAIL can overcome TRAIL-resistance in colon cancer cell lines. Anticancer Res. 2011;31:3385-3394.
41. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001;299:31-38.
42. Cao R, Xue Y, Hedlund EM, Zhong Z, Tritsaris K, Tondelli B, Lucchini F, Zhu Z, Dissing S, Cao Y. VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci USA. 2010;107:856-861.
43. Kano MR, Morishita Y, Iwata C, Iwasaka S, Watabe T, Ouchi Y, Miyazono K, Miyazawa K. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci. 2005;118:3759-3768.